Isofol Medical Logo

Isofol Medical

ISOFOL | ST

Overview

Corporate Details

ISIN(s):
SE0009581051
LEI:
549300MCXYAHG7VBHX75
Country:
Sweden
Address:
C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Isofol Medical is a clinical-stage biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company's lead drug candidate, arfolitixorin, is being developed to increase the efficacy of standard first-line chemotherapy treatments for various solid tumors. Its primary clinical program is investigating arfolitixorin in the treatment of colorectal cancer, where there is a significant unmet medical need for more effective therapies. The company is advancing the drug through clinical studies, including a Phase Ib/II study to optimize its dosing regimen and therapeutic effect. Isofol Medical was founded in 2008 based on a research partnership.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Isofol Medical. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-26 08:00
Interim Report
Swedish 7.2 MB
2025-08-26 08:00
Interim Report
English 2.6 MB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Isofol
Swedish 60.6 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Isofol
English 61.3 KB
2025-07-04 18:00
Regulatory News Service
Isofol's rights issue fully subscribed – exercises overallotment for Japanese p…
English 128.5 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofols företrädesemission övertecknad – utnyttjar övertilldelning till japansk…
Swedish 127.3 KB
2025-06-17 08:40
Prospectus
Isofol offentliggör prospekt i samband med bolagets företrädesemission
Swedish 98.7 KB
2025-06-17 08:40
Prospectus
Isofol publishes prospectus in connection with the company’s rights issue
English 119.6 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
English 94.5 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 11 juni 2025
Swedish 74.5 KB
2025-06-05 08:30
Share Issue/Capital Change
Isofol offentliggör slutliga villkor i företrädesemission samt för en potentiel…
Swedish 142.5 KB
2025-06-05 08:30
Share Issue/Capital Change
Isofol announces final terms of the rights issue and the potential overallotmen…
English 167.4 KB
2025-05-21 16:40
Post-Annual General Meeting Information
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21…
English 95.5 KB
2025-05-21 16:40
Post-Annual General Meeting Information
Kommuniké från årsstämma i Isofol Medical AB (publ) den 21 maj 2025
Swedish 90.1 KB
2025-05-21 08:00
Quarterly Report
Swedish 725.3 KB

Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Isofol Medical via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-11 Magnus Hurst Other Buy 35,000 24,150.00 SEK
2022-09-12 AB Windar Other Buy 500,000 305,000.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 858.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 152.79 SEK
2021-06-14 HealthCom GmbH Other Buy 233,336 1,493,350.40 SEK
2021-06-10 Gustaf Albèrt Other Other 15,153 96,979.20 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 43,487.58 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 29,971.17 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 43,487.58 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 29,971.17 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN